Trials / Completed
CompletedNCT00338936
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) -
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 362 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- —
Summary
This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients. The 350 patients (approximately) who have successfully finished the core trial CVAH631B1303 and signed consent for the extension will be enrolled into this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valsartan + Hydrochlorothiazide |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2006-06-20
- Last updated
- 2011-11-08
Source: ClinicalTrials.gov record NCT00338936. Inclusion in this directory is not an endorsement.